262 related articles for article (PubMed ID: 28581487)
1. EMMPRIN (CD147) is induced by C/EBPβ and is differentially expressed in ALK+ and ALK- anaplastic large-cell lymphoma.
Schmidt J; Bonzheim I; Steinhilber J; Montes-Mojarro IA; Ortiz-Hidalgo C; Klapper W; Fend F; Quintanilla-Martínez L
Lab Invest; 2017 Sep; 97(9):1095-1102. PubMed ID: 28581487
[TBL] [Abstract][Full Text] [Related]
2. Identification of C/EBPβ target genes in ALK+ anaplastic large cell lymphoma (ALCL) by gene expression profiling and chromatin immunoprecipitation.
Bonzheim I; Irmler M; Klier-Richter M; Steinhilber J; Anastasov N; Schäfer S; Adam P; Beckers J; Raffeld M; Fend F; Quintanilla-Martinez L
PLoS One; 2013; 8(5):e64544. PubMed ID: 23741337
[TBL] [Abstract][Full Text] [Related]
3. Oncogenic role of miR-155 in anaplastic large cell lymphoma lacking the t(2;5) translocation.
Merkel O; Hamacher F; Griessl R; Grabner L; Schiefer AI; Prutsch N; Baer C; Egger G; Schlederer M; Krenn PW; Hartmann TN; Simonitsch-Klupp I; Plass C; Staber PB; Moriggl R; Turner SD; Greil R; Kenner L
J Pathol; 2015 Aug; 236(4):445-56. PubMed ID: 25820993
[TBL] [Abstract][Full Text] [Related]
4. CD147 a direct target of miR-146a supports energy metabolism and promotes tumor growth in ALK+ ALCL.
Montes-Mojarro IA; Steinhilber J; Griessinger CM; Rau A; Gersmann AK; Kohlhofer U; Fallier-Becker P; Liang HC; Hofmann U; Haag M; Klapper W; Schaeffeler E; Pichler BJ; Schwab M; Fend F; Bonzheim I; Quintanilla-Martinez L
Leukemia; 2022 Aug; 36(8):2050-2063. PubMed ID: 35676454
[TBL] [Abstract][Full Text] [Related]
5. NPM-ALK-dependent expression of the transcription factor CCAAT/enhancer binding protein beta in ALK-positive anaplastic large cell lymphoma.
Quintanilla-Martinez L; Pittaluga S; Miething C; Klier M; Rudelius M; Davies-Hill T; Anastasov N; Martinez A; Vivero A; Duyster J; Jaffe ES; Fend F; Raffeld M
Blood; 2006 Sep; 108(6):2029-36. PubMed ID: 16709933
[TBL] [Abstract][Full Text] [Related]
6. HuR-mediated control of C/EBPbeta mRNA stability and translation in ALK-positive anaplastic large cell lymphomas.
Bergalet J; Fawal M; Lopez C; Desjobert C; Lamant L; Delsol G; Morello D; Espinos E
Mol Cancer Res; 2011 Apr; 9(4):485-96. PubMed ID: 21343335
[TBL] [Abstract][Full Text] [Related]
7. The heat shock protein-90 co-chaperone, Cyclophilin 40, promotes ALK-positive, anaplastic large cell lymphoma viability and its expression is regulated by the NPM-ALK oncoprotein.
Pearson JD; Mohammed Z; Bacani JT; Lai R; Ingham RJ
BMC Cancer; 2012 Jun; 12():229. PubMed ID: 22681779
[TBL] [Abstract][Full Text] [Related]
8. NPM-ALK and the JunB transcription factor regulate the expression of cytotoxic molecules in ALK-positive, anaplastic large cell lymphoma.
Pearson JD; Lee JK; Bacani JT; Lai R; Ingham RJ
Int J Clin Exp Pathol; 2011 Jan; 4(2):124-33. PubMed ID: 21326808
[TBL] [Abstract][Full Text] [Related]
9. Molecular characterization of the t(2;5) (p23; q35) translocation in anaplastic large cell lymphoma (Ki-1) and Hodgkin's disease.
Yee HT; Ponzoni M; Merson A; Goldstein M; Scarpa A; Chilosi M; Menestrina F; Pittaluga S; de Wolf-Peeters C; Shiota M; Mori S; Frizzera G; Inghirami G
Blood; 1996 Feb; 87(3):1081-8. PubMed ID: 8562933
[TBL] [Abstract][Full Text] [Related]
10. C/EBPβ expression in ALK-positive anaplastic large cell lymphomas is required for cell proliferation and is induced by the STAT3 signaling pathway.
Anastasov N; Bonzheim I; Rudelius M; Klier M; Dau T; Angermeier D; Duyster J; Pittaluga S; Fend F; Raffeld M; Quintanilla-Martinez L
Haematologica; 2010 May; 95(5):760-7. PubMed ID: 20015877
[TBL] [Abstract][Full Text] [Related]
11. A new fusion gene TPM3-ALK in anaplastic large cell lymphoma created by a (1;2)(q25;p23) translocation.
Lamant L; Dastugue N; Pulford K; Delsol G; Mariamé B
Blood; 1999 May; 93(9):3088-95. PubMed ID: 10216106
[TBL] [Abstract][Full Text] [Related]
12. Prognostic significance and therapeutic potential of the activation of anaplastic lymphoma kinase/protein kinase B/mammalian target of rapamycin signaling pathway in anaplastic large cell lymphoma.
Gao J; Yin M; Zhu Y; Gu L; Zhang Y; Li Q; Jia C; Ma Z
BMC Cancer; 2013 Oct; 13():471. PubMed ID: 24112608
[TBL] [Abstract][Full Text] [Related]
13. Next-generation sequencing identifies deregulation of microRNAs involved in both innate and adaptive immune response in ALK+ ALCL.
Steinhilber J; Bonin M; Walter M; Fend F; Bonzheim I; Quintanilla-Martinez L
PLoS One; 2015; 10(2):e0117780. PubMed ID: 25688981
[TBL] [Abstract][Full Text] [Related]
14. Coexpression of MCT1 and MCT4 in ALK-positive Anaplastic Large Cell Lymphoma: Diagnostic and Therapeutic Implications.
Choi JW; Lee Y; Kim H; Cho HY; Min SK; Kim YS
Am J Surg Pathol; 2022 Feb; 46(2):241-248. PubMed ID: 34619707
[TBL] [Abstract][Full Text] [Related]
15. The oncogenic JUNB/CD30 axis contributes to cell cycle deregulation in ALK+ anaplastic large cell lymphoma.
Atsaves V; Lekakis L; Drakos E; Leventaki V; Ghaderi M; Baltatzis GE; Chioureas D; Jones D; Feretzaki M; Liakou C; Panayiotidis P; Gorgoulis V; Patsouris E; Medeiros LJ; Claret FX; Rassidakis GZ
Br J Haematol; 2014 Nov; 167(4):514-23. PubMed ID: 25145835
[TBL] [Abstract][Full Text] [Related]
16. MicroRNA expression profiling identifies molecular signatures associated with anaplastic large cell lymphoma.
Liu C; Iqbal J; Teruya-Feldstein J; Shen Y; Dabrowska MJ; Dybkaer K; Lim MS; Piva R; Barreca A; Pellegrino E; Spaccarotella E; Lachel CM; Kucuk C; Jiang CS; Hu X; Bhagavathi S; Greiner TC; Weisenburger DD; Aoun P; Perkins SL; McKeithan TW; Inghirami G; Chan WC
Blood; 2013 Sep; 122(12):2083-92. PubMed ID: 23801630
[TBL] [Abstract][Full Text] [Related]
17. Gene-expression profiling of systemic anaplastic large-cell lymphoma reveals differences based on ALK status and two distinct morphologic ALK+ subtypes.
Lamant L; de Reyniès A; Duplantier MM; Rickman DS; Sabourdy F; Giuriato S; Brugières L; Gaulard P; Espinos E; Delsol G
Blood; 2007 Mar; 109(5):2156-64. PubMed ID: 17077326
[TBL] [Abstract][Full Text] [Related]
18. Transcripts of the npm-alk fusion gene in anaplastic large cell lymphoma, Hodgkin's disease, and reactive lymphoid lesions.
Elmberger PG; Lozano MD; Weisenburger DD; Sanger W; Chan WC
Blood; 1995 Nov; 86(9):3517-21. PubMed ID: 7579458
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic efficacy of the bromodomain inhibitor OTX015/MK-8628 in ALK-positive anaplastic large cell lymphoma: an alternative modality to overcome resistant phenotypes.
Boi M; Todaro M; Vurchio V; Yang SN; Moon J; Kwee I; Rinaldi A; Pan H; Crescenzo R; Cheng M; Cerchietti L; Elemento O; Riveiro ME; Cvitkovic E; Bertoni F; Inghirami G;
Oncotarget; 2016 Nov; 7(48):79637-79653. PubMed ID: 27793034
[TBL] [Abstract][Full Text] [Related]
20. Nucleophosmin-anaplastic lymphoma kinase: the ultimate oncogene and therapeutic target.
Werner MT; Zhao C; Zhang Q; Wasik MA
Blood; 2017 Feb; 129(7):823-831. PubMed ID: 27879258
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
